<DOC>
	<DOCNO>NCT00598481</DOCNO>
	<brief_summary>This phase I/II protocol evaluate safety efficacy ADA gene transfer hematopoietic stem/progenitor cell treatment adenosine deaminase ( ADA ) -deficiency . This condition autosomal recessive form Severe Combined Immunodeficiency ( SCID ) characterize impaired immune response , recurrent infection , failure thrive systemic toxicity due accumulation purine metabolite . Transplants HLA-identical sibling donor treatment choice , available minority patient . The use alternative bone marrow donor enzyme replacement therapy associate important drawback . The drug product study protocol consist autologous CD34+ hematopoietic stem/progenitor cell engineer ex vivo retroviral vector encode therapeutic gene ADA . The engineered CD34+ cell infuse follow nonmyeloablative condition busulfan make space bone marrow . The study objective : ) evaluate safety clinical efficacy gene therapy , absence enzyme replacement therapy ; b ) evaluate biological activity ( engraftment , ADA expression ) ADA transduce CD34+ cell hematopoietic progeny . c ) evaluate immunological reconstitution purine metabolism gene therapy .</brief_summary>
	<brief_title>ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells Treatment ADA-SCID</brief_title>
	<detailed_description>The safety study evaluate description adverse event adverse drug reaction . The study aim reach minimum sample size ten patient . Long term follow patient enrol study long term follow period 4 8 year gene therapy</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>ADASCID HLAidentical sibling donor pediatric age least one follow criterion : inadequate immune response PEGADA &gt; 6 month patient discontinue PEGADA due intolerance , allergy autoimmunity patient enzyme replacement therapy life long therapeutic option Long term followup Patients receive treatment Medicinal Product , either part main clinical study , previous pilot study compassionate use program HIV infection history current malignancy Patients receive previous gene therapy treatment 12 month prior receive GSK2696273 condition dangerous patient accord investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>SCID</keyword>
	<keyword>gene therapy</keyword>
	<keyword>Adenosine deaminase</keyword>
	<keyword>retroviral vector</keyword>
</DOC>